10:05 AM EST - Medicenna Therapeutics Corp. : Announced that updated clinical data from the ongoing Phase 1/2 ABILITY-1 study were presented today at the 2024 Immunotherapy Bridge held in Naples, Italy. The oral presentation by Dr Arash Yavari, MB BS, DPhil, included new data highlighting the first complete response (CR) in the combination dose escalation phase of the study in a 70-year-old patient with advanced anal squamous cell carcinoma. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.17 at $1.83.
